These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 3141503)
1. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma. Glennie MJ; Brennand DM; Bryden F; McBride HM; Stirpe F; Worth AT; Stevenson GT J Immunol; 1988 Nov; 141(10):3662-70. PubMed ID: 3141503 [TBL] [Abstract][Full Text] [Related]
2. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo. French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599 [TBL] [Abstract][Full Text] [Related]
4. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688 [TBL] [Abstract][Full Text] [Related]
5. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448 [TBL] [Abstract][Full Text] [Related]
6. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia. Flavell DJ; Warnes S; Noss A; Flavell SU Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737 [TBL] [Abstract][Full Text] [Related]
7. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice. Flavell DJ; Warnes SL; Noss AL; Flavell SU Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577 [TBL] [Abstract][Full Text] [Related]
8. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411 [TBL] [Abstract][Full Text] [Related]
9. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848 [TBL] [Abstract][Full Text] [Related]
10. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056 [TBL] [Abstract][Full Text] [Related]
11. Surface immunoglobulins are involved in the interaction of protein A with human B cells and in the triggering of B cell proliferation induced by protein A-containing Staphylococcus aureus. Romagnani S; Giudizi MG; Biagiotti R; Almerigogna F; Maggi E; Del Prete G; Ricci M J Immunol; 1981 Oct; 127(4):1307-13. PubMed ID: 6974188 [TBL] [Abstract][Full Text] [Related]
12. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain. Ramakrishnan S; Houston LL Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765 [TBL] [Abstract][Full Text] [Related]
13. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells. Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403 [TBL] [Abstract][Full Text] [Related]
14. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies. Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380 [TBL] [Abstract][Full Text] [Related]
15. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin. Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234 [TBL] [Abstract][Full Text] [Related]
16. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. French RR; Bell AJ; Hamblin TJ; Tutt AL; Glennie MJ Leuk Res; 1996 Jul; 20(7):607-17. PubMed ID: 8795695 [TBL] [Abstract][Full Text] [Related]
17. Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line. Flavell DJ; Cooper S; Morland B; Flavell SU Br J Cancer; 1991 Aug; 64(2):274-80. PubMed ID: 1716453 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules. Flavell DJ; Cooper S; Morland B; French R; Flavell SU Br J Cancer; 1992 Apr; 65(4):545-51. PubMed ID: 1373293 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line. Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895 [TBL] [Abstract][Full Text] [Related]
20. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin. Glennie MJ; McBride HM; Stirpe F; Thorpe PE; Worth AT; Stevenson GT J Exp Med; 1987 Jul; 166(1):43-62. PubMed ID: 3110351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]